Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | USP8 | P40818 | 2/20 | 0.36 |
| ▸ | PREP | P48147 | 4/20 | 0.34 |
| ▸ | NAAA | Q02083 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17257082 | 1.00 | NPC1 (0.41) | NPC1RAB9ACTSLCTSBCTSK | |
| SCHEMBL17256879 | 0.76 | — | — | |
| SCHEMBL17257009 | 0.74 | MAPK1 (0.39) | RAB9ACTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL17257012 | 0.74 | MAPK1 (0.39) | RAB9ACTSLCTSBCTSKSMN1; SMN2 | |
| SCHEMBL212265 | 0.74 | NPC1 (0.51) | NPC1RAB9AHSD11B1 | |
| SCHEMBL17257367 | 0.70 | — | — | |
| SCHEMBL11006655 | 0.66 | CTSL (0.49) | CTSLCTSBCTSKPREPNAAA | |
| SCHEMBL17257085 | 0.66 | NPC1 (0.47) | NPC1RAB9ACTSLCTSBCTSK | |
| SCHEMBL17257083 | 0.66 | NPC1 (0.47) | NPC1RAB9ACTSLCTSBCTSK | |
| SCHEMBL17257417 | 0.65 | NPC1 (0.42) | NPC1RAB9ACTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | BRIDGESTONE CORPORATION (JP) | 2018-07-24 | — | — | US | claimed |
| EP-3143055-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | Bridgestone Corporation (JP) | 2017-03-22 | — | — | EP | claimed |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | US | claimed |
| WO-2015175280-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | WO | claimed |
| EP-3143055-B1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORP (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | BRIDGESTONE CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| EP-3143055-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | Bridgestone Corporation (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | US | disclosed |
| WO-2015175280-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10030083-B2 | Polymers functionalized with protected oxime compounds containing a cyano group | PAM, PPOX, MB | NPC1 4775/4885RAB9A 4587/4885CTSL 2805/4885 |
| US-20150329655-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | PAM, PPOX, MB | NPC1 4775/4885RAB9A 4587/4885CTSL 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.